논문검색
Author Eui Bae Kim, M.D.1, Dae Sik Kim, M.D.1, Seh Jong Park, M.D.1, Yong Park, M.D.1, Kyoung Ho Rho, M.D.2 and Seok Jin Kim, M.D., Ph.D.1
Place of duty Departments of 1Internal Medicine and 2Laboratory Medicine, Korea University College of Medicine, Seoul, Korea
Title Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy
Publicationinfo Cancer Res Treat 2008 Mar; 040(01): 36-37.
Key_word Rituximab, Hepatitis B virus, Lymphoma
Full-Text
Abstract Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/ HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOPchemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases. (Cancer Res Treat. 2008;40:36-38)
출판정보 대한암학회지 2008 Mar; 040(01): 36-37.